Inhibikase Therapeutics, Inc. announced the publication of studies describing the potential of IkT-148009 as a disease-modifying therapy for Parkinson's disease and related disorders. The publication entitled "The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease" was published online in the journal Science Translational Medicine on January 18, 2023 (DOI: 10.1126 scitranslmed.abp9352). Key highlights included: Demonstration of enzyme selectivity within the c-Abl family for IkT-148009, Implementation of a functional neurodegenerative screen enabling identification of IkT-148009 as a potential therapeutic to suppress c-Abl activation in the brain, Demonstration that IkT-148009 is therapeutically active as a disease-modifying treatment in animal models of PD at the same doses being evaluated in the 201 trial, Provides clarity on how misfolded protein aggregates initiate and progress neurodegenerative diseases and Correlates removal of protein aggregates following c-Abl inhibition by IkT-148009 with functional recovery in multiple models of human disease, a long sought goal of treatment.